Abstract
Recently, wild-type SV40 and/or DNA sequences indistinguishable from SV40 have been detected in specific types of human tumors: ependymoma and choroid plexus tumors, mesothelioma, osteosarcoma and sarcoma. The same tumor types will develop in hamsters after injection with SV40. These findings are interesting in themselves for they could shed light on the pathogenesis of these tumors. These findings also have public health implications. SV40 was found to have contaminated the poliovaccines and the adenovaccines from 1955 until 1963, therefore resulting in the inadvertent injection of millions of people with this tumor virus. Moreover, our society pays a high cost for asbestos causality, a carcinogen associated with the development of mesothelioma. In addition to asbestos, the potential impact of finding another possible cause for mesothelioma (i.e., SV40), as well as the possible pathogenic role of the contaminated poliovaccines, has generated considerable public interest and concern. To discuss these recent findings, the NIH (National Institutes of Health) and the FDA (Food and Drug Administration), organized an International Conference at the NIH, Bethesda, MD, January 27 – 28, 1997. The association of SV40 with human mesothelioma was also discussed in a special session at the IV International Mesothelioma Conference that was held at the University of Pennsylvania, Philadelphia, PA, May 13 – 16, 1997. The purpose of this review is to summarize data, from the discovery of the contaminated poliovaccines, to the most recent findings presented at the meetings in Bethesda and Philadelphia, to discuss technical and other problems associated with this research, and the potential for using these findings to develop new diagnostic and therapeutic approaches for SV40- associated malignancies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40
Orphanet Journal of Rare Diseases Open Access 07 November 2006
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carbone, M., Rizzo, P. & Pass, H. Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene 15, 1877–1888 (1997). https://doi.org/10.1038/sj.onc.1201375
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1201375
Keywords
- SV40
- poliovaccines
- human tumors
This article is cited by
-
High prevalence of antibodies reacting to mimotopes of Simian virus 40 large T antigen, the oncoprotein, in serum samples of patients affected by non-Hodgkin lymphoma
Cancer Immunology, Immunotherapy (2017)
-
Epidemiology of SV-40 Simian Virus in Different Regions of the Russian Federation
Bulletin of Experimental Biology and Medicine (2009)
-
Occurrence of TRGV-BJ hybrid gene in SV40-transformed fibroblast cell lines
Genetica (2009)
-
Evidence for a role of the Simian Virus 40 in human breast carcinomas
Breast Cancer Research and Treatment (2009)
-
Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40
Orphanet Journal of Rare Diseases (2006)